DiaMedica Therapeutics Inc.
DMAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401040
No open-market purchases or sales by DiaMedica Therapeutics Inc. insiders were filed in the last 90 days; 88 institutions reported holding it in 13F filings for Q2 2026, worth $87.8M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding DiaMedica Therapeutics Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 38 | 32 | −6 |
| Shares | 3.84M | 4.60M | +756.5K (+19.7%) |
| Value | $10.9M | $12.7M | +$1.82M (+16.7%) |
New holders (1)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 1,926 | $5.33K | 0.00% |
Sold out (7)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Altium Capital Management LP | 287,698 | $817.1K |
| Millennium Management LLC | 28,845 | $81.9K |
| Avantax Advisory Services, Inc. | 12,500 | $35.5K |
| Group One Trading, L.P. | 4,843 | $13.8K |
| JPMorgan Chase & Co | 564 | $1.60K |
| Simplex Trading, LLC | 481 | $1.00K |
| Bank of America Corp | 15 | $43 |